



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January - March 2011

Liverpool Addiction & Offender Health Team

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT

The final version will be available on the IAD website

Acknowledgements:

The Authors would like to thank the NDTMS and DIP teams for their valuable support. We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
2nd Floor, Henry Cotton Campus,
15-21 Webster Street, Liverpool.
L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith
IAD Researcher

(0151) 231 4309

S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	Page
Introduction	1
Arrest Referral	2
Table 1: Individuals assessed, by Gender & Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Needle and Syringe Programmes (NSPs)	4
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users Omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users Omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users Omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted	
Table 12: Main Drug of Use for New NSP Clients, by Gender	
Table 13: Main Drug of Use for All NSP Clients, by Gender	
Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender	
Table 15: Main Drug of Use, for New NSP Clients, by Age Group	
Pharmacy	10
Table 22: Individuals by Gender	
Table 23: Individuals by Age Group	
Table 24: Year to Date; by Gender & Age Group	
Combined	11
Table 25: Individuals in Agency and Pharmacy NSP, by Gender	
Table 26: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted	
Table 27: Individuals in Agency and Pharmacy NSP, by Age Group	
Table 28: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted	
Table 29: Year to Date, by Gender & Age Group	
Table 30: Combined Pharmacy and Agency NSP Total Syringes Provided	
NSP Service Activity Summary	13
Table 31: All NSP transactions by NSP Type	
Fig 1: NSP Service Activity; Transactions by NSP Type	

Table 32: NSP Transactions, Attributable Data

Table 33: All NSP Individuals by NSP Type

Fig 2: NSP Service Activity; Individuals by NSP Type

National Drug Treatment Monitoring System (NDTMS) 15

Table 34: Individuals in Contact with Treatment Services, by Gender

Table 35: Year to Date, by Gender

Table 36: Individuals in Contact with Treatment Services, by Age Group

Table 37: Year to Date, by Age Group

Table 38: Ethnicity of Individuals in Contact with Treatment Services

Table 39: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 18

Combined Datasets 19

Table 40: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 41: Year to Date Problem Drug Users, by Gender & Age Group

Cross Matched Datasets 20

Fig 3: Crossover between Agency NSP and NDTMS datasets

Fig 4: Crossover between Pharmacy NSP and NDTMS datasets

Fig 5: Crossover between YTD Agency NSP and NDTMS datasets

Fig 6: Crossover between YTD Pharmacy NSP and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2010/11)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request..

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	395	88.0
Female	54	12.0
Age Group		
Under 18	0	0.0
18-19	25	5.6
20-24	109	24.3
25-29	93	20.7
30-34	62	13.8
35-39	66	14.7
40-44	56	12.5
45+	38	8.5
Total	449	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	92	6.4	9	3.7	101	6.0
20-24	353	24.6	34	14.1	387	23.1
25-29	289	20.1	23	9.5	312	18.6
30-34	197	13.7	39	16.2	236	14.1
35-39	203	14.1	62	25.7	265	15.8
40-44	168	11.7	42	17.4	210	12.5
45+	134	9.3	32	13.3	166	9.9
Total	1,436	100	241	100	1,677	100

Table 3: Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	0	0
Benzodiazepines	0	0	0
Cannabis	27	5	2
Crack	12	6	5
Cocaine	16	57	169
Ecstasy	0	0	0
Heroin	55	24	10
Methadone	3	0	0
Other	0	0	0

58 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2010/11)

Introduction

Data are collected directly from needle and syringe programmes (NSPs). Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

Data from Armistead Street were not available in time to be included in this section, however they are reported on page 11 of this report.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	34	97.1
Female	1	2.9
Total	35	100
All Clients		
Male	148	93.7
Female	10	6.3
Total	158	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	9	90.0
Female	1	7.1
Total	10	100
All Clients		
Male	48	18.7
Female	9	22.0
Total	57	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	2.9	1	0.6
20-24	8	22.9	16	10.1
25-29	7	20.0	33	20.9
30-34	5	14.3	28	17.7
35-39	9	25.7	35	22.2
40-44	1	2.9	19	12.0
45+	4	11.4	26	16.5
Total	35	100	158	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	0	0.0	2	3.5
25-29	1	10.0	4	7.0
30-34	3	30.0	8	14.0
35-39	4	40.0	14	24.6
40-44	0	0.0	11	19.3
45+	2	20.0	18	31.6
Total	10	100	57	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	0.7	0	0.0
20-24	15	10.1	1	10.0
25-29	33	22.3	0	0.0
30-34	27	18.2	1	10.0
35-39	31	20.9	4	40.0
40-44	17	11.5	2	20.0
45+	24	16.2	2	20.0
Total	148	100	10	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	2.1	1	11.1
25-29	4	8.3	0	0.0
30-34	7	14.6	1	11.1
35-39	11	22.9	3	33.3
40-44	9	18.8	2	22.2
45+	16	33.3	2	22.2
Total	48	100	9	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	13	2.6	0	0.0	13	2.4
20-24	59	11.8	4	9.8	63	11.7
25-29	112	22.4	4	9.8	116	21.5
30-34	93	18.6	10	24.4	103	19.1
35-39	96	19.2	10	24.4	106	19.6
40-44	61	12.2	7	17.1	68	12.6
45+	65	13.0	6	14.6	71	13.1
Total	499	100	41	100	540	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	0.8	0	0.0	1	0.6
20-24	4	3.0	3	9.1	7	4.2
25-29	10	7.5	2	6.1	12	7.2
30-34	17	12.8	8	24.2	25	15.1
35-39	35	26.3	9	27.3	44	26.5
40-44	31	23.3	7	21.2	38	22.9
45+	35	26.3	4	12.1	39	23.5
Total	133	100	33	100	166	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	8	23.5	1	11.1
Methadone	0	0.0	0	0.0
Steroids	25	73.5	0	0.0
Morphine	0	0.0	0	0.0
Unknown	1	2.9	0	0.0
Total	34	100	1	100

Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	39	26.4	7	70.0
Methadone	3	2.0	0	0.0
Morphine	0	0.0	0	0.0
Steroids	100	67.6	1	10.0
Unknown	2	4.1	2	20.0
Total	148	100	10	100

Current Quarter; Melanotan Clients

- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0 Male clients reported using melanotan during Q4
- 0 Female clients reported using melanotan during Q4

Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	1	0.2	1	2.6
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	0.2	0	0.0
Crack	1	0.2	1	2.6
Heroin	116	23.3	27	69.2
Methadone	7	1.4	1	2.6
Morphine	0	0.0	0	0.0
Steroids	364	73.2	6	15.4
Unknown	7	1.4	3	0.0
Total	497	100	39	100

Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Cocaine (incl Crack)		Heroin		Methadone		Steroids		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	14	13.9	2	25.0
25-29	0	0.0	0	0.0	2	4.3	0	0.0	29	28.7	2	25.0
30-34	0	0.0	0	0.0	7	15.2	0	0.0	20	19.8	1	12.5
35-39	0	0.0	0	0.0	13	28.3	0	0.0	21	20.8	1	12.5
40-44	0	0.0	0	0.0	11	23.9	0	0.0	8	7.9	0	0.0
45+	0	0.0	0	0.0	13	28.3	3	100	8	7.9	2	25.0
Total	0	0	0	0	46	100	3	100	101	100	8	100

* % Totals are by drug, not Age Group

PHARMACY NSPs

Table 22: Individuals by Gender

New Clients	n	%
Male	768	87.9
Female	106	12.1
Total	874	100
All Clients		
Male	1,372	86.1
Female	221	13.9
Total	1,593	100

Table 23: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	< 1	4	< 1
18-19	10	1.1	12	< 1
20-24	117	13.4	181	11.4
25-29	179	20.5	285	17.9
30-34	138	15.8	245	15.4
35-39	163	18.6	326	20.5
40-44	140	16.0	295	18.5
45+	124	14.2	245	15.4
Total	874	100	1,593	100

Table 24: Year to Date; by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	20	< 1	2	< 1	22	< 1
18-19	64	1.3	12	1.4	76	1.3
20-24	600	12.3	71	8.1	671	11.7
25-29	881	18.1	97	11.0	978	17.0
30-34	769	15.8	123	14.0	892	15.5
35-39	985	20.3	239	27.1	1,224	21.3
40-44	879	18.1	172	19.5	1,051	18.3
45+	662	13.6	165	18.7	827	14.4
Total	4,860	100	881	100	5,741	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency, Pharmacy and Armistead datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 25: Individuals in Agency and Pharmacy NSP, by Gender

New Clients	n	%
Male	800	88.3
Female	106	11.7
Total	906	100
All Clients		
Male	1,503	86.9
Female	227	13.1
Total	1,730	100

Table 26: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	776	88.0
Female	106	12.0
Total	882	100
All Clients		
Male	1,408	86.2
Female	226	13.8
Total	1,634	100

*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 27: Individuals in Agency and Pharmacy NSP , by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	0.3	4	0.2
18-19	11	1.2	13	0.8
20-24	124	13.7	195	11.3
25-29	186	20.5	317	18.3
30-34	142	15.7	269	15.5
35-39	171	18.9	355	20.5
40-44	141	15.6	309	17.9
45+	128	14.1	268	15.5
Total	906	100	1,730	100

Table 28: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	0.3	4	0.2
18-19	10	1.1	12	0.7
20-24	117	13.3	182	11.1
25-29	180	20.4	288	17.6
30-34	140	15.9	250	15.3
35-39	166	18.8	336	20.6
40-44	140	15.9	302	18.5
45+	126	14.3	260	15.9
Total	882	100	1,634	100

Table 29: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	20	0.4	2	0.2	22	100
18-19	77	1.5	12	1.3	89	1.4
20-24	646	12.2	74	8.1	720	11.6
25-29	988	18.7	102	11.2	1,090	17.6
30-34	851	16.1	128	14.1	979	15.8
35-39	1,063	20.1	251	27.6	1,314	21.2
40-44	921	17.4	174	19.1	1,095	17.7
45+	716	13.6	168	18.4	884	14.3
Total	5,282	100	911	100	6,193	100

Table 30: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	6,526	76,543	83,069	212,724

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

Table 31: All NSP transactions by NSP Type

All Transactions	n	%
Croxteth CDT	241	5.6
Maryland Centre	133	3.1
Pharmacy NSPs	3,898	91.3
Total	4,272	100

Fig 1: NSP Service Activity; Transactions by NSP Type




Table 32: NSP Transactions, Attributable Data


All Transactions	n	%*
Croxteth CDT	236	6.2
Maryland Centre	123	3.2
Pharmacy NSPs	3,472	90.6
Total	3,831	100

*Represents proportion of transactions that were attributable during the current quarter.

Table 33: All NSP Individuals by NSP Type

All Clients	n	%
Croxteth CDT	62	3.5
Maryland Centre	96	5.5
Pharmacy NSPs	1,593	91.0
Total	1,751	100

Fig 2: NSP Service Activity; Individuals by NSP Type



National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (20010/11)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

Table 34: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	616	75.2
Female	203	24.8
Total	819	100
All Clients		
Male	3,921	72.8
Female	1,464	27.2
Total	5,385	100

Table 35: Year to Date, by Gender

New Clients	n	%
Male	2,149	76.0
Female	678	24.0
Total	2,827	100
All Clients		
Male	4,231	73.0
Female	1,562	27.0
Total	5,793	100

Table 36: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	113	13.8	517	9.6
18-19	20	2.4	153	2.8
20-24	69	8.4	439	8.2
25-29	69	8.4	515	9.6
30-34	118	14.4	817	15.2
35-39	145	17.7	1,229	22.8
40-44	148	18.1	974	18.1
45+	137	16.7	741	13.8
Total	819	100	5,385	100

Table 37: Year to Date, Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	405	14.3	550	9.5
18-19	118	4.2	166	2.9
20-24	311	11.0	483	8.3
25-29	335	11.9	552	9.5
30-34	404	14.3	869	15.0
35-39	498	17.6	1,311	22.6
40-44	413	14.6	1,063	18.3
45+	343	12.1	799	13.8
Total	2,827	100	5,793	100

Table 38: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	724	88.4	4,777	88.7
White Irish	3	< 1	33	< 1
Other White	8	1.0	41	< 1
White & Black Caribbean	1	< 1	30	< 1
White and Black African	2	< 1	12	< 1
African	2	< 1	9	< 1
White & Asian	3	< 1	9	< 1
Other Asian	4	< 1	22	< 1
Other Mixed	6	< 1	33	< 1
Caribbean	1	< 1	10	< 1
Other Black	10	1.2	70	1.3
Chinese	2	< 1	5	< 1
Other	10	1.2	37	< 1
Unknown	43	5.3	297	5.5
Total	819	100	5,385	100

Table 39: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	398	48.6	3,218	59.8
Methadone	44	5.4	136	2.5
Other Opiates	12	1.5	49	< 1
Benzodiazepines	4	< 1	15	< 1
Amphetamines	6	< 1	40	< 1
Cocaine	102	12.5	772	14.3
Crack	34	4.2	149	2.8
Hallucinogens	2	< 1	5	< 1
Ecstasy	1	< 1	7	< 1
Cannabis	202	24.7	961	17.8
Antidepressants	9	1.1	12	< 1
Prescription Drugs	3	< 1	3	< 1
Other/Unknown	2	< 1	18	< 1
Total	819	100	5,385	100

CONNEXIONS

Quarter 4 (2010/11)

Background

Due to changes in Data Sharing protocols we were unable to access Connexions data in time for this report.

COMBINED DATASETS

Quarter 4 (2010/11)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies.

Table 40: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	5,173	76.1
Female	1,629	23.9
Age Group		
Under 18	521	7.7
18-19	163	2.4
20-24	621	9.1
25-29	799	11.7
30-34	1,037	15.2
35-39	1,482	21.8
40-44	1,223	18.0
45+	956	14.1
Total	6,802	100

Table 41: Year to Date, by Gender and Age Group

	Gender				<i>Total in Age Group</i>	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	478	5.0	92	3.8	570	4.8
18-19	256	2.7	42	1.7	298	2.5
20-24	1,157	12.1	211	8.7	1,368	11.4
25-29	1,442	15.1	254	10.5	1,696	14.2
30-34	1,426	14.9	379	15.7	1,805	15.1
35-39	1,857	19.4	630	26.1	2,487	20.8
40-44	1,642	17.2	441	18.3	2,083	17.4
45+	1,302	13.6	366	15.2	1,668	13.9
Total	9,560	100	2,415	100	11,975	100

CROSS-MATCHED DATASETS

Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.

Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets




Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets




Fig 5: Year to Date Crossover between Agency NSP and NDTMS datasets




Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

